A preclinical study demonstrated that human guanylyl cyclase C (GUCY2C)-targeted CAR-T cells triggered T-cell activation, exerted antitumour effects and alleviated CRLM in both syngeneic and human CRC xenograft murine models [287]. This evidence concerns the gene GUCY2C and colorectal carcinoma.